Histone deacetylase inhibitors (HDI) are among the growing class of epigenetic therapies used for the treatment of cancer. Although histone deacetylase inhibitors (HDIs) are effective in the treatment
SHP2 mediates signaling from multiple receptor tyrosine kinases (RTKs) to extracellular signal-regulated kinase (ERK) and Ser and Thr kinase AKT, and its inhibitors offer an unprecedented opportunity
Global mRNA expression profiling of patient derived colon cancer xenograft models (N=10) showing disease control under cetuximab treatment were collected using Agilent human whole genome array (G484